Silexion shareholders approve 50M share increase, expanded equity plan, and 1-for-10 reverse split

Silexion Therapeutics Corp

Authorized shares increased from 9M to 59M via Memorandum Amendment effective May 5, 2026.
Equity incentive plan evergreen provision raised from 5% of outstanding to pool of 10% fully diluted shares annually.
Reverse stock split at 1-for-10 approved; can be reduced to maintain Nasdaq minimum public float.
All three proposals passed with ~61% of votes in favor at reconvened meeting with 40.2% quorum.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Silexion Therapeutics Corp: Increase in authorized share capital from $121,500 divided into 9,000,000 ordinary shares to $796,500 divided into 59,000,000 ordinary shares (effective 2026-05-05).

Change: charter amendment
Effective: 2026-05-05

Exact text from the filing

At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silexion Therapeutics Corp shareholders approved Amendment to the Silexion Therapeutics Corp 2024 Equity Incentive Plan to increase the number of ordinary shares added annually under the evergreen provision at the 2026-05-05 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-05-05

Exact text from the filing

The result of the vote on the Evergreen Increase Proposal was as follows: Number of Votes and % of Votes in Favor (Excluding Abstentions) Number of Votes and % of Votes Against (Excluding Abstentions) Abstentions 1,000,423 (61.4%) 629,411 (38.6%) 8,245

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silexion Therapeutics Corp shareholders approved Increase to the authorized share capital of the Company by 50,000,000 ordinary shares at the 2026-05-05 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2026-05-05

Exact text from the filing

The result of the vote on the Authorized Share Capital Increase Proposal was as follows: Number of Votes and % of Votes in Favor (Excluding Abstentions) Number of Votes and % of Votes Against (Excluding Abstentions) Abstentions 1,005,128 (61.4%) 632,491 (38.6%) 460

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silexion Therapeutics Corp shareholders approved Reverse share split of the Company's ordinary shares at a ratio of 1-for-10 at the 2026-05-05 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2026-05-05

Exact text from the filing

The result of the vote on the Reverse Share Split Proposal was as follows : Number of Votes and % of Votes in Favor (Excluding Abstentions) Number of Votes and % of Votes Against (Excluding Abstentions) Abstentions 1,004,667 (61.3%) 633,152 (38.7%) 260

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Silexion Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001178913-26-002393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.